Responsive Neurostimulation for the Treatment of Refractory Focal Epilepsy

This policy covers responsive neurostimulation (FDA‑approved NeuroPace RNS System) for treatment of refractory focal epilepsy in adults (≥18 years) with 1–2 well‑localized seizure foci who have averaged ≥3 disabling seizures per month over the prior 3 months, have failed ≥2 appropriate antiepileptic drugs, and are not candidates for focal resective surgery. Coverage excludes patients <18 years, those with generalized or multiple/unlocalized foci, fewer than the required seizure frequency, candidates for resection, or those with contraindications to device placement, and benefit plan terms, state regulations, and investigational/exclusionary provisions in the policy govern final coverage.

"Responsive neurostimulation (RNS) for the treatment of refractory focal epilepsy."

Sign up to see full coverage criteria, indications, and limitations.